A pharmaceutical company in the Triangle is raising funds to advance its clinical programs a few months after initiating a process to review the company's path forward. Tenax Therapeutics (Nasdaq: TENX) on Friday announced the pricing of a public offering that's expected to total gross proceeds of about $15.6 million.